Key result
Bucindolol reduced mortality by 38% (P=0.03) and mortality or hospitalization by 34% (P=0.004) in heart failure patients who were beta1AR Arg-389 homozygotes, with no response in Gly-389 carriers.
Why the study?
Does bucindolol reduce mortality and hospitalization in heart failure patients depending on their beta1AR-389 genotype?
Population
1,040 heart failure patients genotyped for beta1-adrenergic receptor polymorphism, as well as transfected…
Comparison
Bucindolol vs Placebo
Design
RCT, null, Placebo-controlled
Authors
Loading...
Supports genotype-guided bucindolol use in select HF patients; extends RCT evidence for beta1AR polymorphism effects on beta-blocker response.
RCT (n=1,040)
Does bucindolol reduce mortality and hospitalization in heart failure patients depending on their beta1AR-389 genotype?
Effect estimate: 38% reduction
p-value: p=0.03
The beta1AR-389 polymorphism significantly alters the therapeutic response to the beta-blocker bucindolol in heart failure, suggesting a potential role for genotype-guided individualized treatment.
Liggett et al. (2006) conducted an RCT in Heart failure (n=1,040). Bucindolol vs. Placebo was evaluated on Mortality (38% reduction, p=0.03). Bucindolol reduced mortality by 38% (P=0.03) and mortality or hospitalization by 34% (P=0.004) in heart failure patients who were beta1AR Arg-389 homozygotes, with no response in Gly-389 carriers.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: